Total raised
$37.0M
Last: Series C 2021-11
Stage
Series C
Founded
2016
Headcount
36
HQ
—
Sector
Health Tech & Life Sciences
About
Biond Biologics is a biotechnology company developing immunotherapies and an intracellular drug delivery platform for the treatment of cancer patients.
The company uses biologics targeting novel immune evasion mechanisms, discovered through in-house research utilizing real-world patient and tumor samples. Biond Biologics is developing an intracellular delivery platform for biologics (e.g., antibodies or enzymes) inside cells, allowing the company to drug intracellular targets currently considered "undruggable."
Funding history · 3 rounds · $37.0M total
2021-11
Series C
$15.0M
2019-01
Series B
$17.0M
Date unknown
Series A
$5.0M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
pharmaceuticalsimmunologydrug-discoveryoncologyautoimmune-diseasesbiopharmaceuticalcancerpharma-companiesimmunotherapy